Is Redhill Biopharma Ltd. (RDHL) Stock Halal or Haram?
Redhill Biopharma Ltd. (RDHL) - Not Halal (Non-Compliant)
Redhill Biopharma Ltd. (RDHL) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Result
Pass
Reason
The sector "Healthcare" and industry "Drug Manufacturers - Specialty & Generic" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 11.7% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio
Value: 43.4% | Threshold: 30% | Result: Fail
Non-Permissible Income Ratio
Value: 1.6% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 1.59%.Based on the company's financial statements, approximately 1.59% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.59% of total income). Some scholars may differ on the exact calculation method.
About Redhill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Based on the company's financial statements, approximately 1.59% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.59% of total income). Some scholars may differ on the exact calculation method.
Uses quarterly data
About Redhill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
IsraelNASDAQHealthcare
Screened using AAOIFI Standard No. 21 on October 20, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Aug 31, 2026. We started recording changes on Oct 19, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Redhill Biopharma Ltd. (RDHL) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Redhill Biopharma Ltd.'s interest income ratio is 43.4% of total revenue. AAOIFI standards require this to be below 30%.
RDHL is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Redhill Biopharma Ltd.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
You can save RDHL to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Dividends from Redhill Biopharma Ltd. require purification. Approximately 1.59% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
Is Redhill Biopharma Ltd. (RDHL) stock halal to invest in?
According to AAOIFI Shariah screening standards, Redhill Biopharma Ltd. (RDHL) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Does Redhill Biopharma Ltd. have any interest income?
Redhill Biopharma Ltd.'s interest income ratio is 43.4% of total revenue. AAOIFI standards require this to be below 30%.
What guidelines are used to determine if RDHL stock is Shariah-compliant?
RDHL is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Redhill Biopharma Ltd. stock reviewed for Shariah compliance?
Redhill Biopharma Ltd.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Redhill Biopharma Ltd.'s compliance status?
You can save RDHL to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Are dividends from Redhill Biopharma Ltd. stock considered halal?
Dividends from Redhill Biopharma Ltd. require purification. Approximately 1.59% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Do I need to pay Zakat on my Redhill Biopharma Ltd. shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
